KMID : 0939920180500010195
|
|
´ëÇѾÏÇÐȸÁö 2018 Volume.50 No. 1 p.195 ~ p.203
|
|
An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
|
|
Lee Shin-Wha
Kim Yong-Man Cho Chi-Heum Kim Young-Tae Kim Seok-Mo Hur Soo-Young Kim Jae-Hoon Kim Byoung-Gie Kim Seung-Cheol Ryu Hee-Sug Kang Soon-Beom
|
|
Abstract
|
|
|
Purpose: Genexol-PM is a biodegradable cremophor EL?free polymeric micelle formulation of paclitaxel. Here,we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment.
Materials and Methods: In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3weeks (6 cycles). The primary endpointwas the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR).
Results: Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00¡¾0.00 mg/m2 Genexol-PM or 174.24¡¾3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ¡Ã grade 3 occurred in one patient receiving Genexol. All toxicities were manageable.
Conclusion: Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.
|
|
KEYWORD
|
|
Genexol-PM, Genexol, Carboplatin, Phase II trial, Ovarian neoplasms
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|